| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/11/2013 | CA2848584A1 Template-fixed peptidomimetics as inhibitors of fpr1 |
| 04/11/2013 | CA2843520A1 Fibroblast growth factor 21 variants |
| 04/10/2013 | EP2578603A1 B cell activating factor antagonist and preparation method and use thereof |
| 04/10/2013 | EP2578598A1 Componds derived from normuramyldipeptide |
| 04/10/2013 | EP2578597A1 Novel cyclic peptide compound, method for producing same, anti-infective agent, antibiotic-containing fraction, antibiotic, method for producing antibiotic, antibiotic-producing microorganism, and antibiotic produced by same |
| 04/10/2013 | EP2578234A1 Sugar responsive gel and medicine administering device |
| 04/10/2013 | EP2578228A2 Non-diffusive botulinum toxin causing local muscle paralysis, and purification method thereof |
| 04/10/2013 | EP2578227A2 Cancer therapy method |
| 04/10/2013 | EP2578226A1 Peptide inhibitors for mediating stress responses |
| 04/10/2013 | EP2578225A1 Specific Therapy and Medicament Using Integrin Ligands for Treating Cancer |
| 04/10/2013 | EP2578224A1 Cell growth-promoting peptide and use thereof |
| 04/10/2013 | EP2576790A1 Vitronectin:keratinocyte growth factor chimeras |
| 04/10/2013 | EP2576776A1 Modified beta-lactamases and methods and uses related thereto |
| 04/10/2013 | EP2576624A1 Recombinant human g-csf dimer and use thereof for the treatment of neurological diseases |
| 04/10/2013 | EP2576614A2 Class i mhc phosphopeptides for cancer immunotherapy and diagnosis |
| 04/10/2013 | EP2576610A2 Biomarker for diagnosis and treatment of colorectal cancer |
| 04/10/2013 | EP2576608A1 Fraction of proteins and peptides derived from egg white and protein derived from egg white and use thereof as anti-listeria agent |
| 04/10/2013 | EP2576598A1 Nociceptin mimetics |
| 04/10/2013 | EP2576597A1 Rhamm binding peptides |
| 04/10/2013 | EP2576596A1 Peptide for use as a medicament, in particular for the treatment of cancer |
| 04/10/2013 | EP2576592A1 Preparation of crystalline ezatiostat hydrochloride ansolvate form d |
| 04/10/2013 | EP2576591A2 Tablet formulation of ezatiostat |
| 04/10/2013 | EP2576590A1 Crystalline ezatiostat hydrochloride ansolvate |
| 04/10/2013 | EP2575891A1 Formulations preserving bioactivity and methods of their preparation |
| 04/10/2013 | EP2575888A2 Nasal immunization |
| 04/10/2013 | EP2575883A2 Treatment of inflammatory disorders |
| 04/10/2013 | EP2575866A1 Inhibitors of hcv ns5a |
| 04/10/2013 | EP2575865A1 Pharmaceutical composition comprising ave0010 and insulin glargine |
| 04/10/2013 | EP2575864A1 Trefoil factors (tff) for the treatment of chronic pulmonary diseases |
| 04/10/2013 | EP2575863A2 Use of the sparc microenvironment signature in the treatment of cancer |
| 04/10/2013 | EP2575862A2 Neuregulin isoforms, neuregulin polypeptides and uses thereof |
| 04/10/2013 | EP2575861A1 A novel synergistic pharmaceutical composition for topical applications |
| 04/10/2013 | EP2575860A1 Diagnostic, screening and therapeutic applications of ocab-based tools |
| 04/10/2013 | EP2575859A1 Methods of treating diabetes and compositions capable of same |
| 04/10/2013 | EP2575858A2 Methods for treatment of nephrotic syndrome and related conditions |
| 04/10/2013 | EP2575857A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases |
| 04/10/2013 | EP2575856A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases |
| 04/10/2013 | EP2575855A2 Methods for treating or preventing vascular graft failure |
| 04/10/2013 | EP2575854A1 Cyclosporin emulsions |
| 04/10/2013 | EP2575853A1 Methods and pharmaceutical composition for the treatment of a feeding disorder with early-onset in a patient |
| 04/10/2013 | EP2575852A1 Antimicrobial peptides and peptide derivatives derived from oncopeltus fasciatus |
| 04/10/2013 | EP2575851A1 Novel anticancer agents comprising peptides with cancer-specific toxicity |
| 04/10/2013 | EP2575850A1 Improved cancer therapy based on tumor associated antigens derived from cyclin d1 |
| 04/10/2013 | EP2575849A2 An expeditious synthesis of ubiquitinated peptide conjugates |
| 04/10/2013 | EP2575848A2 Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications |
| 04/10/2013 | EP2575847A1 Methods of purifying polypeptides |
| 04/10/2013 | EP2575846A1 Insulin-like growth factor 1 receptor binding peptides |
| 04/10/2013 | EP2575845A2 Aqueous formulations for coating microneedle arrays |
| 04/10/2013 | EP2575805A2 Methods of treatment |
| 04/10/2013 | EP2575803A1 Methods of treating bladder cancer |
| 04/10/2013 | EP2575776A1 Process for making dry and stable hemostatic compositions |
| 04/10/2013 | EP2575775A1 Process for making dry and stable hemostatic compositions |
| 04/10/2013 | EP2575762A2 Removal of serine proteases by treatment with finely divided silicon dioxide |
| 04/10/2013 | EP2575501A2 Stable high lipid liquid formula |
| 04/10/2013 | EP2575496A1 Collagen powder |
| 04/10/2013 | CN103038351A Vitronectin:keratinocyte growth factor chimeras |
| 04/10/2013 | CN103038341A Modified beta-lactamases and methods and uses related thereto |
| 04/10/2013 | CN103038250A 胰高血糖素类似物 Glucagon analogs |
| 04/10/2013 | CN103038248A RHAMM binding peptides |
| 04/10/2013 | CN103037901A Cd36 inhibition to control obesity and insulin sensitivity |
| 04/10/2013 | CN103037895A Manufacture of active highly phosphorylated human N-acetylgalactosamine-6-sulfatase and uses thereof |
| 04/10/2013 | CN103037894A Lactoferrin sequences, compositions and methods of corneal wound treatment |
| 04/10/2013 | CN103037893A Treatment of coagulopathy with hyperfibrinolysis |
| 04/10/2013 | CN103037892A Compositions and methods for inducing angiogenesis |
| 04/10/2013 | CN103037891A Methods of treating diabetes and compositions capable of same |
| 04/10/2013 | CN103037890A Dendritic cell inhibitory proteins from ticks |
| 04/10/2013 | CN103037889A Peptide having antimicrobial or anti-inflammatory activity and pharmaceutical composition containing same as an active ingredient |
| 04/10/2013 | CN103037888A Treatment of proliferative diseases |
| 04/10/2013 | CN103037887A Methods and pharmaceutical compositions for the treatment of respiratory tract infections |
| 04/10/2013 | CN103037886A Cosmetic uses of modified stressed yeast extracts and related compositions |
| 04/10/2013 | CN103037885A Compositions and methods related to protein A (SpA) variants |
| 04/10/2013 | CN103037884A Pharmaceutical or neutraceutical formulation |
| 04/10/2013 | CN103037873A Method for producing autologous proteins |
| 04/10/2013 | CN103037872A Composition for treatment of damaged part |
| 04/10/2013 | CN103037847A Process for making dry and stable hemostatic compositions |
| 04/10/2013 | CN103037840A Lipid membrane structure with nuclear transferability |
| 04/10/2013 | CN103037712A Stable high lipid liquid formula |
| 04/10/2013 | CN103031359A Application of S100 group protein |
| 04/10/2013 | CN103031292A MsCT-AcAPc2 fusion protein for treating osteoporosis and thrombi and nucleic acid encoding fusion protein |
| 04/10/2013 | CN103030690A Improved human interferon molecules and their uses |
| 04/10/2013 | CN103030688A Short chain polypeptide for inhibiting cancer cell growth as well as encoding gene and application of short chain polypeptide |
| 04/10/2013 | CN103030687A Anti-inflammatory active peptide Hydrostatin-SN1 derived from Hydrophis cyanocinctus, coding gene thereof and application in pharmacy |
| 04/10/2013 | CN103030684A Novel bleomycin analogue as well as preparation method and application thereof |
| 04/10/2013 | CN103030683A Peptaibol and preparation method and use thereof |
| 04/10/2013 | CN103030680A Novel anti-hepatitis C virus inhibitor and preparation method thereof |
| 04/10/2013 | CN103030636A Macrocyclic inhibitors of hepatitis c virus |
| 04/10/2013 | CN103028110A Novel use of antisecretory factor |
| 04/10/2013 | CN102613567B Soybean peptide nutrient solution and preparation method and application thereof |
| 04/10/2013 | CN102552177B Freeze-dried recombinant human brain natriuretic peptide (rhBNP) preparation and preparation method thereof |
| 04/10/2013 | CN102429890B Medicinal composition containing cells and application thereof |
| 04/10/2013 | CN102408472B Bt (Bacillus Thuringiensis) protein Cry62Aa1 and coding gene as well as application thereof |
| 04/10/2013 | CN102397258B Insulin carrying microsphere and preparation method thereof |
| 04/10/2013 | CN102389566B Huidouba peptide polysaccharide-containing composition used for treating type II diabetes |
| 04/10/2013 | CN102321157B Hexapeptide with antioxidant activity and separation method as well as application thereof |
| 04/10/2013 | CN102242138B Recombination expression of cynoglossus semilaevis antibacterial peptide hepcidin and application thereof |
| 04/10/2013 | CN102228437B Co-immobilized TNF-a/IFN-g/DOX/FA/Fe3O4-OA magnetic targeted nanoparticle as well as preparation method and application thereof |
| 04/10/2013 | CN102178939B Muramidase hydrolase external sterile cream for treating skin ulcer and preparation method thereof |
| 04/10/2013 | CN102178937B Pharmaceutical composition for protecting liver and benefiting spleen and preparation method thereof |
| 04/10/2013 | CN102133395B Skeleton health-care product or medicinal composite and application thereof |
| 04/10/2013 | CN102105148B Therapeutic combination comprising an AURORA kinase inhibitor and antiproliferative agents |